schizandrin has been researched along with ginsenoside rb1 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Y; Fan, X; Guo, W; Li, Z; Shao, Q; Zhan, S | 1 |
| Cao, G; Cao, Z; Guo, Z; Kou, J; Li, L; Yang, H; Yu, B; Zhou, H | 1 |
| Chen, HL; Kou, JP; Li, F; Lv, YN; Shen, K; Tan, YS; Yu, BY; Zhai, KF | 1 |
| Fan, X; Kou, J; Li, F; Ma, X; Pang, L; Song, M; Yu, B; Zhang, Y | 1 |
| Chu, C; Fan, XX; Kou, JP; Li, F; Yu, BY; Zhang, Y | 1 |
| Kou, J; Lai, Q; Li, F; Yang, W; Yu, B; Zhang, L; Zhang, Y | 1 |
6 other study(ies) available for schizandrin and ginsenoside rb1
| Article | Year |
|---|---|
A pharmacokinetic and pharmacodynamic study of drug-drug interaction between ginsenoside Rg1, ginsenoside Rb1 and schizandrin after intravenous administration to rats.
Topics: Administration, Intravenous; Animals; Area Under Curve; Chromatography, High Pressure Liquid; Cyclooctanes; Drug Interactions; Drug Synergism; Ginsenosides; Half-Life; Lignans; Male; Medicine, Chinese Traditional; Models, Biological; Nitric Oxide; Panax; Polycyclic Compounds; Rats; Rats, Sprague-Dawley; Schisandra | 2014 |
A combination of four active compounds alleviates cerebral ischemia-reperfusion injury in correlation with inhibition of autophagy and modulation of AMPK/mTOR and JNK pathways.
Topics: Adenine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Autophagy; Brain; Brain Infarction; Cyclooctanes; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drugs, Chinese Herbal; Ginsenosides; Infarction, Middle Cerebral Artery; Lignans; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Polycyclic Compounds; Renal Circulation; Reperfusion Injury; Saponins; Time Factors; TOR Serine-Threonine Kinases | 2014 |
An integrated pathway interaction network for the combination of four effective compounds from ShengMai preparations in the treatment of cardio-cerebral ischemic diseases.
Topics: Animals; Brain Ischemia; Cell Line; Cyclooctanes; Drug Combinations; Drugs, Chinese Herbal; Ginsenosides; Humans; Lignans; Myocardial Ischemia; NF-kappa B; Oxidative Stress; PC12 Cells; Polycyclic Compounds; Protein Interaction Maps; Rats; Saponins; Signal Transduction; Systems Biology; Tumor Necrosis Factor-alpha | 2015 |
Cardioprotection by combination of three compounds from ShengMai preparations in mice with myocardial ischemia/reperfusion injury through AMPK activation-mediated mitochondrial fission.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cardiotonic Agents; Cyclooctanes; Drug Combinations; Drug Therapy, Combination; Drugs, Chinese Herbal; Dynamins; Ginsenosides; Lignans; Male; Mice, Inbred ICR; Mitochondrial Dynamics; Myocardial Reperfusion Injury; Polycyclic Compounds; Spirostans | 2016 |
A Strategy for Optimizing the Combination of Active Components Based on Chinese Medicinal Formula Sheng-Mai-San for Myocardial Ischemia.
Topics: Animals; Creatine Kinase, MB Form; Cyclooctanes; Disease Models, Animal; Drug Combinations; Drugs, Chinese Herbal; Ginsenosides; Heart; Isoproterenol; L-Lactate Dehydrogenase; Lignans; Medicine, Chinese Traditional; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Pituitary Hormones, Posterior; Polycyclic Compounds; Spirostans; Troponin I | 2018 |
Mechanisms dissection of the combination GRS derived from ShengMai preparations for the treatment of myocardial ischemia/reperfusion injury.
Topics: Animals; Cell Line; Cell Survival; Cyclooctanes; Drug Combinations; Drugs, Chinese Herbal; Ginsenosides; Inflammation Mediators; Lignans; Male; Mice; Mice, Inbred ICR; Myocardial Reperfusion Injury; Myocytes, Cardiac; Polycyclic Compounds; Rats; Spirostans; Treatment Outcome | 2021 |